USA - engelsk - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - telmisartan (unii: u5syw473rq) (telmisartan - unii:u5syw473rq), amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288) - telmisartan 40 mg - twynsta (telmisartan/amlodipine) tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin ii receptor blockers and dihydropyridine calcium channel blockers. there are no controlled trials demonstrating risk reduction with twynsta. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.87 mg; telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: isomalt; brilliant blue fcf aluminium lake; iron oxide yellow; mannitol; magnesium stearate; calcium hydrogen phosphate; povidone; meglumine; iron oxide black; microcrystalline cellulose; silicon dioxide; croscarmellose sodium; sodium hydroxide - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.94 mg; telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: silicon dioxide; iron oxide yellow; croscarmellose sodium; mannitol; meglumine; brilliant blue fcf aluminium lake; povidone; iron oxide black; microcrystalline cellulose; isomalt; calcium hydrogen phosphate; sodium hydroxide; magnesium stearate - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.94 mg; telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; calcium hydrogen phosphate; microcrystalline cellulose; mannitol; magnesium stearate; iron oxide yellow; isomalt; brilliant blue fcf aluminium lake; silicon dioxide; sodium hydroxide; povidone; meglumine; iron oxide black - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.87 mg; telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; iron oxide yellow; mannitol; isomalt; brilliant blue fcf aluminium lake; iron oxide black; microcrystalline cellulose; povidone; calcium hydrogen phosphate; magnesium stearate; silicon dioxide; meglumine; sodium hydroxide - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.87 mg; telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; povidone; magnesium stearate; citric acid; mannitol; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.935 mg; telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; povidone; magnesium stearate; citric acid; mannitol; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 13.87 mg; telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; povidone; magnesium stearate; citric acid; mannitol; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amlodipine besilate, quantity: 6.935 mg; telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; povidone; magnesium stearate; citric acid; mannitol; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

USA - engelsk - NLM (National Library of Medicine)

solco healthcare us, llc - telmisartan (unii: u5syw473rq) (telmisartan - unii:u5syw473rq) - telmisartan 20 mg - telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of